For those who are confused on the IHub about the R
Post# of 7769
ScripsAmerica holds the exclusive rights to Rapimed and anticipates the launching of its first line of products in Q4 2013. The first RapiMed product to enter the market will be 80mg and 160mg Acetaminophen, which is the base formulation in Tylenol. This product will target children 2-11 years old and provide ease of administration as well as safe and effective dosage applications.